New pill aims to keep narcolepsy patients awake during the day

NCT ID NCT06555783

Completed Symptom relief Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested an experimental drug called ALKS 2680 in 93 adults with narcolepsy type 2, a condition causing severe daytime sleepiness. Participants took either the drug or a placebo daily to see if it safely improved their ability to stay awake. The trial is now complete, and results will show if the drug reduces sleepiness better than a dummy pill.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALKS 2680 (oral tablet)
What this could lead to: If successful, this could lead to a new treatment option to help people with narcolepsy type 2 stay awake during the day.
What could go wrong: This is a small, early-phase trial (93 people) and results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence narcolepsy narcolepsy without cataplexy sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY TYPE 2

Contacts and locations

Locations

Alkermes Investigational Site

Aurora, Colorado, 80045, United States
Alkermes Investigational Site

Macon, Georgia, 31210, United States
Alkermes Investigational Site

Peoria, Illinois, 61637, United States
Alkermes Investigational Site

Cleveland, Ohio, 44195, United States
Alkermes Investigational Site

Philadelphia, Pennsylvania, 19107, United States
Alkermes Investigational Site

Sugar Land, Texas, 77478, United States
Alkermes Investigational Site

Madison, Wisconsin, 53792, United States
Alkermes Investigational Site

Alken, 3570, Belgium
Alkermes Investigational Site

Namur, 5101, Belgium
Alkermes Investigational Site

Prague, 128 21, Czechia
Alkermes Investigational Site

Bordeaux, 33076, France
Alkermes Investigational Site

La Tronche, 38700, France
Alkermes Investigational Site

Bologna, BO, 40139, Italy
Alkermes Investigational Site

Milan, Metropolitan City Of Milan, 20132, Italy
Alkermes Investigational Site

Zwolle, 8025BV, Netherlands
Alkermes Investigational Site

Barcelona, 08036, Spain
Alkermes Investigational Site

Madrid, 28036, Spain
Alkermes Investigational Site

Madrid, 28043, Spain
Alkermes Investigational site

Verona, 37134, Italy
Alkermes Investigator Site

Little Rock, Arkansas, 72211, United States
Alkermes Investigator Site

Los Angeles, California, 90025, United States
Alkermes Investigator Site

Redwood City, California, 94063, United States
Alkermes Investigator Site

San Francisco, California, 94143, United States
Alkermes Investigator Site

Santa Ana, California, 92705, United States
Alkermes Investigator Site

Colorado Springs, Colorado, 80918, United States
Alkermes Investigator Site

Brandon, Florida, 33511, United States
Alkermes Investigator Site

Miami, Florida, 33176, United States
Alkermes Investigator Site

Winter Park, Florida, 32789, United States
Alkermes Investigator Site

Atlanta, Georgia, 30328, United States
Alkermes Investigator Site

Stockbridge, Georgia, 30281, United States
Alkermes Investigator Site

Lansing, Michigan, 48911, United States
Alkermes Investigator Site

Sterling Heights, Michigan, 48314, United States
Alkermes Investigator Site

Lincoln, Nebraska, 68506, United States
Alkermes Investigator Site

Middletown, New Jersey, 07748, United States
Alkermes Investigator Site

Denver, North Carolina, 28037, United States
Alkermes Investigator Site

Huntersville, North Carolina, 28078, United States
Alkermes Investigator Site

Canton, Ohio, 44718, United States
Alkermes Investigator Site

Cincinnati, Ohio, 45212, United States
Alkermes Investigator Site

Cincinnati, Ohio, 45245, United States
Alkermes Investigator Site

Abington, Pennsylvania, 19001, United States
Alkermes Investigator Site

Wyomissing, Pennsylvania, 19610, United States
Alkermes Investigator Site

Columbia, South Carolina, 29201, United States
Alkermes Investigator Site

Cordova, Tennessee, 38108, United States
Alkermes Investigator Site

Austin, Texas, 78731, United States
Alkermes Investigator Site

San Antonio, Texas, 78229, United States
Alkermes Investigator Site

Macquarie Park, New South Wales, 2113, Australia
Alkermes Investigator Site

Bedford Park, South Australia, 5042, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.